Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia

INTRODUCTION: Combination of venetoclax and hypomethylating agents (HMAs) has become a standard of care in acute myeloid leukemia (AML) aged >75 years or who have comorbidities that preclude intensive induction chemotherapy. METHODS: We conducted a monocentric retrospective analysis on adult pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciumè, Mariarita, Bosi, Alessandro, Canzi, Marta, Ceparano, Giusy, Serpenti, Fabio, De Roberto, Pasquale, Fabris, Sonia, Tagliaferri, Elena, Cavallaro, Francesca, Onida, Francesco, Fracchiolla, Nicola Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083332/
https://www.ncbi.nlm.nih.gov/pubmed/37051529
http://dx.doi.org/10.3389/fonc.2023.1149298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083332/
https://www.ncbi.nlm.nih.gov/pubmed/37051529
http://dx.doi.org/10.3389/fonc.2023.1149298

Ejemplares similares